Zenbexus (iberdomide)
An approved treatment for Multiple Myeloma.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify Iberdomide wherever you encounter it, plus the key facts at a glance.
- Generic name
- Iberdomide
- Brand name
- Zenbexus
- Development code
- CC-220
- Drug class
- Cereblon-modulating protein degrader (CELMoD)
- Manufacturer
- Bristol Myers Squibb (Celgene Corporation, a Bristol Myers Squibb company)
- How it's taken
- A capsule taken by mouth once a day for 21 days of each 28-day cycle, with daratumumab and dexamethasone
Zenbexus (iberdomide) is a CELMoD pill, a new kind of protein-degrading medicine, for adults with multiple myeloma that has returned after earlier treatment[1][4].
- The FDA granted Zenbexus accelerated approval on August 13, 2026, for use with daratumumab and hyaluronidase-fihj and dexamethasone after at least 1 prior line that included a proteasome inhibitor and an immunomodulatory agent[2].
- In the EXCALIBER-RRMM trial, 41% of people on the Zenbexus combination reached an MRD-negative complete response, against 21% on daratumumab, bortezomib and dexamethasone[1].
- Zenbexus carries a boxed warning for harm to an unborn baby and for serious blood clots, and it is only available through the Zenbexus REMS program[1].
- Zenbexus is not approved on its own or for newly diagnosed myeloma, and its continued approval may depend on a confirmatory trial showing clinical benefit[1].
We'll email you when Zenbexus's FDA label changes, when the FDA acts on it, and when new trials for Multiple Myeloma open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where Iberdomide fits
The label limits Zenbexus to adults with multiple myeloma who have had at least 1 prior line of therapy that included a proteasome inhibitor and an immunomodulatory agent[1]. Zenbexus is approved only together with daratumumab and hyaluronidase-fihj and dexamethasone, not on its own[1]. The pivotal trial enrolled people after 1 or 2 prior lines and excluded myeloma refractory to an anti-CD38 antibody or to bortezomib[1].
How Iberdomide works
Iberdomide is a cereblon-modulating protein degrader, which the drugmaker calls a CELMoD[1][4]. It binds cereblon, part of the cell's machinery for tagging proteins to be broken down[1]. Once bound, it steers that machinery toward 2 proteins called Ikaros and Aiolos, which switch genes on in myeloma cells and immune cells[1].
Breaking down those proteins has 2 effects described on the label[1]:
In lab studies, adding iberdomide made daratumumab better at helping immune cells and blood proteins attack myeloma cells[1]. Bristol Myers Squibb describes the older immunomodulatory drugs as protein degraders too, and calls Zenbexus the first approved drug in its new CELMoD class[4].
Side effects and safety
- Harm to an unborn baby. Not for use in pregnancy. People who can become pregnant need 2 negative pregnancy tests before starting and 2 forms of birth control from 4 weeks before until 4 weeks after the last dose, or must abstain from heterosexual sex.
- Zenbexus REMS. Prescribers and pharmacies must be certified and patients must enroll and follow its monitoring and birth control rules.
- Blood clots. Vein clots in 6.4% and artery clots in 3.4% despite required prevention; clot-preventing medicine is recommended.
- Neutropenia. Low neutrophils in 90.2%, grade 3 in 30.9% and grade 4 in 53.4%; fever with low neutrophils in 5.4%.
- Infections. Infections in 78.9%, serious in 40% and fatal in 2%; people with an active, uncontrolled infection should not start until it is controlled.
- Second cancers. New cancers in 6.9% on the Zenbexus combination against 4.9% on the comparison regimen at a median of 16 months.
- Pregnancy tests weekly for the first 4 weeks, then every 4 weeks (every 2 weeks with irregular cycles)
- Complete blood counts at the start and throughout treatment
- Signs of blood clots, with clot-preventing medicine chosen by risk
- Signs of infection before and during treatment
- Watching for new cancers
- Kidney function, since the dose is lower with severe kidney impairment
Zenbexus has a boxed warning, the FDA's strongest label warning, for 2 risks[1]:
- Harm to an unborn baby: Zenbexus can cause birth defects or death of an unborn baby, and it must not be taken during pregnancy[1].
- Blood clots: Zenbexus with daratumumab and dexamethasone raises the risk of clots in the legs and lungs, heart attack and stroke, and the label recommends medicine to prevent clots[1].
In EXCALIBER-RRMM, clots in the veins occurred in 6.4% of 204 people on the Zenbexus combination even though clot prevention was required[1]. Clots in the arteries occurred in 3.4%, including heart attack in 2.0% and stroke in 1.5%[1].
Low neutrophil, white blood cell and lymphocyte counts were the most common severe (grade 3 or 4) lab abnormalities[1]. Neutropenia (low neutrophils, the white cells that fight bacteria) occurred in 90.2%, and was grade 4, the most severe level, in 53.4%[1]. Infections occurred in 78.9%, serious infections in 40% and fatal infections in 2%[1]. New cancers (second primary malignancies) occurred in 6.9% on the Zenbexus combination and 4.9% on the comparison regimen at a median follow-up of 16 months[1].
Serious side effects occurred in 58.3% of people who took Zenbexus, most often pneumonia (26%)[1]. Fatal side effects occurred in 10 people (4.9%), and sepsis was the only fatal reaction seen in more than 1 person[1]. Doses were paused for side effects in 84% and lowered in 29%, and 7.8% stopped Zenbexus for good because of side effects[1].
Nerve damage in the hands and feet (sensory neuropathy) was reported in 19% on the Zenbexus combination, against 53% on the bortezomib-based comparison regimen[1]. Serious side effects were more common with age, at 53% under 65, 56% from 65 to 74 and 74% at 75 and older[1].
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Iberdomide
Zenbexus is a capsule taken by mouth, with or without food, together with daratumumab and hyaluronidase-fihj (an injection under the skin) and dexamethasone[1].
The label's schedule, in 28-day cycles[1][2]:
- Zenbexus: 1mg once a day on days 1 to 21, then 7 days off[1].
- Daratumumab and hyaluronidase-fihj: 1800mg weekly in cycles 1 and 2, every 2 weeks in cycles 3 to 6, then on day 1 of each cycle from cycle 7, as given in EXCALIBER-RRMM[1].
- Dexamethasone: 20mg or 40mg by mouth on days 1, 8, 15 and 22, as given in EXCALIBER-RRMM[1].
Treatment continues until the myeloma progresses or side effects become too hard to manage[1]. Capsules are swallowed whole with water and are not opened, broken or chewed[1]. A dose missed by less than 12 hours can be taken late, and a dose missed by more than 12 hours is skipped[1].
The lower 0.75mg capsule is used after some side effects, when a moderate CYP3A inhibitor cannot be avoided, and for severe kidney impairment without dialysis[1]. The label advises avoiding strong or moderate CYP3A inhibitors and inducers, which change iberdomide levels in the blood, and lowers the dose to 1mg every other day if a strong CYP3A inhibitor cannot be avoided[1].
Zenbexus is only available through the Zenbexus REMS program, a restricted program because of the risk to an unborn baby[1]. Prescribers and pharmacies must be certified, patients must enroll, and wholesalers may ship only to certified pharmacies[1]. The label lists www.ZENBEXUSREMS.com and the REMS Call Center at 1-888-423-5436[1]. Patients must not donate blood during treatment or for 4 weeks after the last dose[1].
Availability and cost
Only available as the brand-name product.
Help paying for Zenbexus
With private insurance, the drugmaker's copay card can lower what you pay for Zenbexus. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. Of the 5 charity funds for Multiple Myeloma, 1 was open on October 26, 2026. Pick your insurance below to see which offers fit you.
- Copay help
The BMS Access Support Co-Pay Assistance Program helps commercially insured patients prescribed Zenbexus with out-of-pocket deductibles, co-pays or co-insurance. Eligible patients may pay as little as $0 per one-month supply, subject to a maximum benefit; restrictions apply.
For: private insurance · source - Other support
People with government insurance such as Medicare, Medicaid or TRICARE are not eligible for BMS co-pay programs. BMS Access Support may provide information about, or refer uninsured patients to, independent charitable foundations.
For: Medicare, Medicaid, TRICARE, no insurance · source - Insurance and case manager help
BMS Access Support offers coverage and access assistance and help finding local support resources. Live support at 1-800-861-0048, 8 am to 8 pm ET, Monday to Friday.
The official page does not say who qualifies. Ask the program. · source
Good to know: The co-pay page does not publish the dollar amount of the maximum benefit; full eligibility rules are in the BMS orals Terms and Conditions. Charitable foundations are independent of Bristol Myers Squibb and set their own rules. Zenbexus is dispensed only by pharmacies certified in the Zenbexus REMS program.
Charity funds for Multiple Myeloma
- From a charity · HealthWell FoundationMultiple Myeloma (Medicare Access) fundOpen
Pays for: Copays, premiums or other treatment costs. Medicare patients only.
Clinical trial results
EXCALIBER-RRMM (NCT04975997) is a Phase 3, randomized, open-label trial in adults with relapsed or refractory myeloma after 1 or 2 prior lines of therapy[1][8]. It compares Zenbexus, daratumumab and hyaluronidase-fihj and dexamethasone with daratumumab and hyaluronidase-fihj, bortezomib and dexamethasone (DVd)[1]. People whose myeloma was refractory to an anti-CD38 antibody or to bortezomib were excluded[1].
A total of 939 people were randomized across 2 stages, and the approval rests on the first 420 randomized to Zenbexus 1mg (207) or DVd (213)[1]. In that group, 90% had taken an immunomodulatory drug, 70% lenalidomide, and 95% a proteasome inhibitor[1]. Only 4% had taken an anti-CD38 antibody before, so the label says data in that group are limited[1].
Results on the label[1]:
MRD-negative means no myeloma cells were found at a sensitivity of 1 in 100,000 cells, which the label measured with next-generation flow testing[1]. Bristol Myers Squibb reported on September 24, 2026 an overall response rate of 88.9% against 76.1%, and complete response or better in 45.9% against 24.9%[5]. Progression-free survival is the trial's other primary goal, and progression-free survival results do not appear on the current label[1][5].
Bristol Myers Squibb announced on October 8, 2026 that the trial met that goal, with a median progression-free survival of 42 months against 20 months (hazard ratio 0.49), and Fierce Pharma reported the same results[6][7]. The FDA has not yet reviewed those results for the label.
Development history
Iberdomide was developed under the code CC-220 by Celgene, now part of Bristol Myers Squibb[8][4]. Key dates:
- July 2021: the EXCALIBER-RRMM trial was registered on ClinicalTrials.gov, and it began enrolling in June 2022[8].
- August 13, 2026: the FDA granted accelerated approval with daratumumab and hyaluronidase-fihj and dexamethasone, after a priority review with breakthrough therapy and orphan drug designations[2][3].
- September 24, 2026: Bristol Myers Squibb presented the trial's MRD results at the International Myeloma Society meeting[5].
- October 8, 2026: Bristol Myers Squibb announced that EXCALIBER-RRMM met its progression-free survival goal[6][7].
The FDA said the review ran under Project Orbis, with Switzerland's Swissmedic reviewing at the same time[2]. Bristol Myers Squibb called it the first approval in relapsed or refractory myeloma based on MRD-negative complete response[4]. Because the approval is accelerated, the label says continued approval may depend on a confirmatory trial showing clinical benefit[1].
Explore Multiple Myeloma trials
Other Multiple Myeloma treatments
Bristol Myers Squibb calls Zenbexus the first approved CELMoD and describes the older immunomodulatory drugs, such as lenalidomide and pomalidomide, as protein degraders too. Its pivotal trial compared Zenbexus with bortezomib, each given with daratumumab and hyaluronidase-fihj and dexamethasone, on MRD-negative complete response, and no trial has compared it with other immunomodulatory drug combinations.
After a first relapse, label-approved options also include combinations built on proteasome inhibitors, anti-CD38 antibodies and immunomodulatory drugs. A care team weighs prior treatments, side effects and how each drug is given.
Common questions about Iberdomide
▸What is Iberdomide (Zenbexus)?
Zenbexus (iberdomide) is a CELMoD pill, a new kind of protein-degrading medicine, for adults with multiple myeloma that has returned after earlier treatment[1][4]. The FDA granted Zenbexus accelerated approval on August 13, 2026, for use with daratumumab and hyaluronidase-fihj and dexamethasone after at least 1 prior line that included a proteasome inhibitor and an immunomodulatory agent[2]. In the EXCALIBER-RRMM trial, 41% of people on the Zenbexus combination reached an MRD-negative complete response, against 21% on daratumumab, bortezomib and dexamethasone[1]. Zenbexus carries a boxed warning for harm to an unborn baby and for serious blood clots, and it is only available through the Zenbexus REMS program[1]. Zenbexus is not approved on its own or for newly diagnosed myeloma, and its continued approval may depend on a confirmatory trial showing clinical benefit[1].
▸How does Iberdomide work?
Iberdomide is a cereblon-modulating protein degrader, which the drugmaker calls a CELMoD[1][4]. It binds cereblon, part of the cell's machinery for tagging proteins to be broken down[1]. Once bound, it steers that machinery toward 2 proteins called Ikaros and Aiolos, which switch genes on in myeloma cells and immune cells[1].
Breaking down those proteins has 2 effects described on the label[1]:
- Anti-tumor activity, seen in lab studies in myeloma cells, including cells resistant to lenalidomide and pomalidomide[1].
- Immune effects, including more of the immune-signaling proteins interleukin-2 and interferon-gamma and less of the inflammatory protein interleukin-6[1].
In lab studies, adding iberdomide made daratumumab better at helping immune cells and blood proteins attack myeloma cells[1]. Bristol Myers Squibb describes the older immunomodulatory drugs as protein degraders too, and calls Zenbexus the first approved drug in its new CELMoD class[4].
▸What are the side effects of Iberdomide?
Zenbexus has a boxed warning, the FDA's strongest label warning, for 2 risks[1]: Harm to an unborn baby: Zenbexus can cause birth defects or death of an unborn baby, and it must not be taken during pregnancy[1]. Blood clots: Zenbexus with daratumumab and dexamethasone raises the risk of clots in the legs and lungs, heart attack and stroke, and the label recommends medicine to prevent clots[1].
In EXCALIBER-RRMM, clots in the veins occurred in 6.4% of 204 people on the Zenbexus combination even though clot prevention was required[1]. Clots in the arteries occurred in 3.4%, including heart attack in 2.0% and stroke in 1.5%[1].
Low neutrophil, white blood cell and lymphocyte counts were the most common severe (grade 3 or 4) lab abnormalities[1]. Neutropenia (low neutrophils, the white cells that fight bacteria) occurred in 90.2%, and was grade 4, the most severe level, in 53.4%[1]. Infections occurred in 78.9%, serious infections in 40% and fatal infections in 2%[1]. New cancers (second primary malignancies) occurred in 6.9% on the Zenbexus combination and 4.9% on the comparison regimen at a median follow-up of 16 months[1].
Serious side effects occurred in 58.3% of people who took Zenbexus, most often pneumonia (26%)[1]. Fatal side effects occurred in 10 people (4.9%), and sepsis was the only fatal reaction seen in more than 1 person[1]. Doses were paused for side effects in 84% and lowered in 29%, and 7.8% stopped Zenbexus for good because of side effects[1].
Nerve damage in the hands and feet (sensory neuropathy) was reported in 19% on the Zenbexus combination, against 53% on the bortezomib-based comparison regimen[1]. Serious side effects were more common with age, at 53% under 65, 56% from 65 to 74 and 74% at 75 and older[1].
▸How is Iberdomide taken?
Zenbexus is a capsule taken by mouth, with or without food, together with daratumumab and hyaluronidase-fihj (an injection under the skin) and dexamethasone[1].
The label's schedule, in 28-day cycles[1][2]:
- Zenbexus: 1mg once a day on days 1 to 21, then 7 days off[1].
- Daratumumab and hyaluronidase-fihj: 1800mg weekly in cycles 1 and 2, every 2 weeks in cycles 3 to 6, then on day 1 of each cycle from cycle 7, as given in EXCALIBER-RRMM[1].
- Dexamethasone: 20mg or 40mg by mouth on days 1, 8, 15 and 22, as given in EXCALIBER-RRMM[1].
Treatment continues until the myeloma progresses or side effects become too hard to manage[1]. Capsules are swallowed whole with water and are not opened, broken or chewed[1]. A dose missed by less than 12 hours can be taken late, and a dose missed by more than 12 hours is skipped[1].
The lower 0.75mg capsule is used after some side effects, when a moderate CYP3A inhibitor cannot be avoided, and for severe kidney impairment without dialysis[1]. The label advises avoiding strong or moderate CYP3A inhibitors and inducers, which change iberdomide levels in the blood, and lowers the dose to 1mg every other day if a strong CYP3A inhibitor cannot be avoided[1].
Zenbexus is only available through the Zenbexus REMS program, a restricted program because of the risk to an unborn baby[1]. Prescribers and pharmacies must be certified, patients must enroll, and wholesalers may ship only to certified pharmacies[1]. The label lists www.ZENBEXUSREMS.com and the REMS Call Center at 1-888-423-5436[1]. Patients must not donate blood during treatment or for 4 weeks after the last dose[1].
▸Is Iberdomide FDA approved?
Yes, Iberdomide (Zenbexus) is FDA approved (2026) for the treatment of Multiple Myeloma.
▸Is Zenbexus chemotherapy?
The Zenbexus label does not call it chemotherapy; it calls it a cereblon-modulating protein degrader that breaks down 2 proteins myeloma cells rely on[1].
How it works: Iberdomide binds cereblon and leads to the breakdown of Ikaros and Aiolos, with anti-tumor and immune effects[1].
Given with: The label approves it only together with daratumumab and hyaluronidase-fihj and dexamethasone, a steroid[1].
Class: Bristol Myers Squibb calls it the first approved CELMoD[4].
Source: Zenbexus prescribing information (DailyMed); Bristol Myers Squibb, August 2026
▸How is Zenbexus different from Revlimid or Pomalyst?
Zenbexus belongs to a newer class Bristol Myers Squibb calls CELMoDs, while Revlimid and Pomalyst are immunomodulatory drugs, and no trial has compared Zenbexus with either one head to head[4].
Shared idea: Bristol Myers Squibb describes the older immunomodulatory drugs as protein degraders too[4].
Lab data: The Zenbexus label reports activity in lenalidomide- and pomalidomide-resistant myeloma cells in lab studies[1].
Trial patients: In EXCALIBER-RRMM, 70% had taken lenalidomide and 5% pomalidomide before[1].
Source: Zenbexus prescribing information (DailyMed); Bristol Myers Squibb, August 2026
▸Why does Zenbexus need a REMS program?
Zenbexus can cause birth defects or death of an unborn baby, so the FDA requires the Zenbexus REMS restricted program[1].
Who enrolls: Prescribers and pharmacies must be certified, and patients must enroll and follow monitoring and birth control rules[1].
Pregnancy tests: People who can become pregnant need 2 negative tests before starting, then weekly tests for 4 weeks and regular tests after that[1].
Men: Zenbexus may pass into semen, so the label calls for contraception during treatment and for 4 weeks after[1].
Contact: The label lists www.ZENBEXUSREMS.com and 1-888-423-5436[1].
Source: Zenbexus prescribing information (DailyMed)
▸What does accelerated approval mean for Zenbexus?
Accelerated approval means the FDA approved Zenbexus based on a measure expected to predict benefit, MRD-negative complete response, before longer-term results were in[1].
Trial result: In EXCALIBER-RRMM, 41% on the Zenbexus combination reached MRD-negative complete response against 21% on daratumumab, bortezomib and dexamethasone[1].
What comes next: The label says continued approval may depend on a confirmatory trial showing clinical benefit[1].
Progression-free survival: This is the trial's other primary goal and is not on the current label[1]. Bristol Myers Squibb announced on October 8, 2026 a median of 42 months against 20 months[6].
Source: Zenbexus prescribing information (DailyMed); Bristol Myers Squibb, October 2026
▸Is there help paying for Zenbexus?
Bristol Myers Squibb points patients to BMS Access Support for insurance and cost help, and the price is not stated on the label[10].
Copay help: Eligible commercially insured patients may pay as little as $0 per one-month supply, subject to a maximum benefit[9].
Government plans: People with Medicare, Medicaid or TRICARE are not eligible for BMS co-pay programs, but BMS Access Support can share information on independent charitable foundations[9].
Insurance: BMS Access Support helps patients understand their coverage and find other sources of financial support[10].
Phone: BMS Access Support is at 1-800-861-0048, 8 AM to 8 PM ET, Monday to Friday[10].
Source: Zenbexus financial assistance page; BMS Access Support co-pay page (Bristol Myers Squibb)
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- U.S. National Library of Medicine, DailyMed (E.R. Squibb & Sons, L.L.C., Bristol-Myers Squibb) · 2026-08. ZENBEXUS (iberdomide) capsules, full prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3663d9cb-3f66-48ae-bf0a-6958bc0888de
- U.S. Food and Drug Administration · 2026-08-13. FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-iberdomide-daratumumab-and-hyaluronidase-fihj-and-dexamethasone
- U.S. Food and Drug Administration · 2026-08-13. Drugs@FDA: ZENBEXUS, NDA 221075 (original approval August 13, 2026; priority review, orphan). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=221075
- Bristol Myers Squibb (via Business Wire) · 2026-08. U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse. https://www.businesswire.com/news/home/20260811027471/en/U.S.-FDA-Grants-Accelerated-Approval-to-Bristol-Myers-Squibbs-First-CELMoD-Therapy-ZENBEXUS-in-Combination-with-Daratumumab-and-Hyaluronidase-fihj-and-Dexamethasone-ZDd-for-Patients-with-Multiple-Myeloma-as-Early-as-First-Relapse
- Bristol Myers Squibb (via Business Wire) · 2026-09-24. Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma. https://www.businesswire.com/news/home/20260924614211/en/Bristol-Myers-Squibb-Announces-First-Presentation-of-Results-for-ZENBEXUS-iberdomide-in-Combination-with-Daratumumab-from-Phase-3-EXCALIBER-RRMM-Trial-in-Relapsed-or-Refractory-Multiple-Myeloma
- Bristol Myers Squibb · 2026-10-08. Bristol Myers Squibb Announces ZENBEXUS (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3 EXCALIBER-RRMM Trial. https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Announces-ZENBEXUSTM-iberdomide-in-Combination-with-Daratumumab-and-Dexamethasone-ZDd-Demonstrates-Superior-Progression-Free-Survival-vs--Standard-of-Care-in-Relapsed-and-Refractory-Multiple-Myeloma-in-Phase-3---/default.aspx
- Fierce Pharma · 2026-10-08. BMS fills out Zenbexus picture with post-approval PFS victory in multiple myeloma. https://www.fiercepharma.com/pharma/bms-fills-out-zenbexus-picture-post-approval-pfs-victory-multiple-myeloma
- ClinicalTrials.gov · 2026-11. A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (EXCALIBER-RRMM). https://clinicaltrials.gov/study/NCT04975997
- Bristol Myers Squibb · 2026-11. BMS Access Support: Co-Pay and Financial Support Options (Zenbexus co-pay program). https://www.bmsaccesssupport.com/patient/co-pay-financial-support
- Bristol Myers Squibb · 2026-11. Financial Assistance, ZENBEXUS (iberdomide). https://www.zenbexus.com/support-resources/celmod-financial-assistance